Search

Displaying results 2661 - 2670 of 7687 in total
  1. Drug

    Ifosfamide

    go.drugbank.com/drugs/DB01181
    ApprovedInvestigational

    It is active as an alkylating agent and an immunosuppressive agent.

  2. Drug

    Menadione

    go.drugbank.com/drugs/DB00170
    ApprovedNutraceutical

    A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.

  3. Drug

    Cretostimogene grenadenorepvec

    go.drugbank.com/drugs/DB05148
    Investigational

    CG0070, an oncolytic virus therapy with specificity for multiple cancers, has been evaluated in numerous preclinical studies. … It has been engineered to secrete GM-CSF, an immune stimulating hormone, which also serves as the adjuvant in cancer immunotherapy.

  4. Drug

    Lisdexamfetamine

    go.drugbank.com/drugs/DB01255
    ApprovedInvestigational

    Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine,[A40246] covalently attached to the naturally occurring amino acid L-lysine. … [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009.

  5. Drug

    Cenisertib

    go.drugbank.com/drugs/DB06347
    Investigational

    Cenisertib is an aurora kinase inhibitor.

  6. Drug

    Viralym-C

    go.drugbank.com/drugs/DB17975
    Investigational

    It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241] … Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes.

  7. Drug

    Zileuton

    go.drugbank.com/drugs/DB00744
    ApprovedWithdrawn

    Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth musc...

  8. Drug

    Trabedersen

    go.drugbank.com/drugs/DB05697
    Investigational

    Synonyms: DNA, D(P-THIO)(C-G-G-C-A-T-G-T-C-T-A-T-T-T-T-G-T-A)
  9. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    [A254187] In December 2020, the FDA placed a partial clinical hold and requested the drug developer, Regeneron Pharmaceuticals, to amend clinical protocols to reduce the incidence of CRS. … [A254187,A254197] Preliminary studies have shown that in patients with R/R NHL, the use of odronextamab does not lead to the development of neurologic toxicity; however, it can lead to the development

  10. Drug

    Rusfertide

    go.drugbank.com/drugs/DB17724
    ApprovedInvestigational

    [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.